|
全民健康保險藥品給付規定 |
|
See related Reyataz cap[瑞塔滋 膠囊] information |
|
|
|
製造商 |
Bristol-Myers Squibb |
|
代理/經銷商 |
Bristol-Myers Squibb |
|
成份 |
Atazanavir sulfate |
|
適應症 |
In combination with other antiretroviral agents for the treatment of HIV-1 infection. |
|
用量 |
Adult 400 mg once daily. Coadministration with efavirenz Reyataz 300 mg & ritonavir 100 mg given with efavirenz 600 mg, all as a single daily dose. Coadministration with didanosine buffered formulations Reyataz should be given 2 hr before or 1 hr after didanosine. Coadministration with tenofovir Reyataz 300 mg given with ritonavir 100 mg & tenofovir 300 mg, all as a single daily dose. |
|
過量 |
View Reyataz[瑞塔滋] overdosage for action to be taken in the event of an overdose. |
|
用法 |
Should be taken with food (Swallow whole, do not chew/crush/open.). |
|
美國食品藥物管理局之懷孕等級 |
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters). |
|
禁忌 |
Coadministration with midazolam, triazolam, dihydroergotamine, ergotamine, ergonovine, methylergonovine, cisapride, pimozide. Avoid coadministration with rifampin, irinotecan, lovastatin, simvastatin, indinavir, proton-pump inhibitors, St John's wort. |
|
注意事項 |
Coadministration with drugs primarily metabolized by CYP3A [e.g. Ca channel blockers, HMG-CoA reductase inhibitors, immunosuppressants & phosphodiesterase (PDE5) inhibitors] or UGT1A1 (e.g. irinotecan). Additive effect with other drugs that prolong the PR interval including β-blockers (except atenolol), verapamil & digoxin. Pre-existing cardiac conduction system disease. Diabetes/hyperglycemia. Hepatic impairment including hepatitis B or C viral infections & patients with marked elevations of serum transaminases prior to treatment. Hemophilia type A & B. Pregnancy & lactation.Hepatic impairment including hepatitis B or C viral infections & patients with marked elevations of serum transaminases prior to treatment. Hemophilia type A & B. Pregnancy & lactation. |
|
不良反應 |
Headache, fever, pain, fatigue, back pain, nausea, jaundice/scleral icterus, abdominal pain, vomiting, diarrhea, lipodystrophy, arthralgia, depression, insomnia, dizziness, peripheral neurologic symptoms, increased cough, rash.
View ADR Monitoring Website[參閱藥物不良反應監測表格] |
|
交互作用 |
Drugs that should not be coadministered with Reyataz: rifampin, irinotecan, midazolam, triazolam, dihydroergotamine, ergotamine, ergonovine, methylergonovine, cisapride, lovastatin, simvastatin, pimozide, indinavir, proton-pump inhibitors, St John's Wort. Drugs that may require or may cause alteration in dose or regimen if coadministered with Reyataz: didanosine buffered formulations, tenofovir, efavirenz, nevirapine, saquinavir, ritonavir, other protease inhibitors, antacids & buffered medications, antiarrhythmics (amiodarone, bepridil, systemic lidocaine, quinidine), warfarin, tricyclic antidepressants, ketoconazole & itraconazole, voriconazole, rifabutin, Ca channel blockers (e.g. diltiazem, felodipine, nifedipine, nicardipine, verapamil), atorvastatin, H2-receptor antagonists, immunosuppressants (cyclosporin, sirolimus, tacrolimus), clarithromycin, ethinyl estradiol & norethindrone, PDE5 inhibitors (sildenafil, tadalafil, vardenafil).
View more drug interactions with Reyataz[瑞塔滋] |
|
儲存 |
View Reyataz[瑞塔滋] storage conditions for details to ensure optimal shelf-life. |
|
描述 |
View Reyataz[瑞塔滋] description for details of the chemical structure and excipients (inactive components). |
|
作用 |
View Reyataz[瑞塔滋] mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
本商品之市售規格 |
|
劑型 |
包裝 |
圖片 |
|
Reyataz 膠囊 |
|
Reyataz 150 mg x 60's |
 |
|
Reyataz 200 mg x 60's |
 |
|
|
|
Manufacturer: |
Bristol-Myers Squibb |
|
Distributor: |
Bristol-Myers Squibb |
|
|
|
|
|
